Omega Therapeutics (NASDAQ:OMGA), headquartered in Cambridge, Massachusetts, is a clinical‐stage biotechnology company focused on the development of gene control therapies using its proprietary Synthetic Epigenetic Regulation platform. The company’s OMEGA platform is designed to precisely modulate gene expression by targeting regulatory elements and epigenetic marks within the genome, offering a distinct approach to treating diseases through durable and selective gene control.
Omega’s pipeline includes multiple preclinical and clinical programs addressing inflammatory, metabolic, respiratory and hematologic disorders. Lead therapeutic candidates aim to either upregulate or downregulate disease‐associated genes by leveraging high-resolution epigenomic maps and structure-based design. This method provides an alternative to traditional gene editing and gene replacement strategies, potentially reducing off-target effects and improving safety profiles.
Founded in 2016, Omega has built a research and development infrastructure that spans discovery, manufacturing and translational sciences. The company collaborates with academic institutions and industry partners to advance its platform and expand the scope of epigenetic therapies. While based in the United States, Omega’s research efforts extend to international centers of excellence to accelerate program timelines and foster innovation.
Omega’s leadership is comprised of scientists and industry veterans with deep expertise in molecular biology, drug development and regulatory affairs. Allen E. Hill, President and Chief Executive Officer and co-founder of the company, brings over two decades of experience in biotechnology innovation. Supported by a board of directors featuring former pharmaceutical executives and academic leaders, Omega Therapeutics is poised to advance its pipeline and transform therapeutic modalities through targeted gene control.
